Intraprostatic PSMA PET/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026-07 · 53 (8) · 4905-4912
DOI: 10.1007/s00259-026-07839-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 23.03.2026. Verfasst von Holger Einspieler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron-Emission Tomography, Magnetic Resonance Imaging, Multimodal Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
PURPOSE: PSMA PET/MRI pairs high sensitivity for PSMA-avid lesions with superior soft-tissue contrast and provides quantitative metrics that may predict clinical outcomes of prostate cancer (PCa). We investigated whether intraprostatic PET-derived metrics and PSA-based variables predict histopathological ISUP grade and biochemical recurrence (BCR) after radical prostatectomy (RPE). METHODS: Men with primary PCa who underwent [⁶⁸Ga]PSMA PET/MRI before RPE were retrospectively analyzed. PET-derived tumor metrics, initial PSA (iPSA), PSA density (PSAD), and ISUP grade were assessed for association with tumor aggressiveness and BCR. Discriminatory performance was evaluated using ROC AUCs. Multivariable logistic regression retained the better-performing variable within correlated pairs (e.g., SUVpeak vs. SUVmax). Kaplan–Meier and Cox models examined recurrence-free survival. RESULTS: Among 101 men, all evaluated parameters differentiated low- (ISUP 1–2) from high-grade (ISUP 3–5) disease, with PET metrics showing the highest AUCs. In multivariable analysis, SUVpeak independently predicted high-grade disease (OR 1.3, 95% CI 1.1–1.5, p < 0.001). Follow-up was available for 71 patients (mean 3.2 ± 2.8 years); 36 (51%) developed BCR after 2.7 ± 2.6 years. For BCR prediction, all variables except SUVmax showed significant AUCs. In multivariable models, ISUP (OR 1.8, 95% CI 1.2–2.9, p = 0.01) and PSAD (OR 4.0, 95% CI 1.1–15.0, p = 0.039) remained significant. The combined model (ISUP + SUVpeak + PSAD) achieved an AUC of 0.788 (95% CI 0.678–0.898, p < 0.001). In Cox analysis, only high ISUP grade independently predicted time to BCR (HR 3.2, 95% CI 1.2–8.9, p = 0.02). CONCLUSION: Intraprostatic PET metrics, especially SUVpeak, effectively assess tumor aggressiveness before RPE, while PSAD adds prognostic value for recurrence. Postoperative ISUP grade remains the strongest predictor of BCR. Combined imaging and PSA-based markers may improve risk stratification and warrant validation in prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
- Department of Biomedical Imaging and Image-Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Vienna, 1090, Austria.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA.
- Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan.
- Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
ORCID-Profile: Sazan Rasul
Förderung
- Medical University of Vienna
Zitieren
APA
Einspieler, H., Nürnberger, M., Spielvogel, C. P., Nics, L., Baltzer, P. A. T., Huebner, N., Kramer, G., Shariat, S. F., Grubmüller, B., Hacker, M., & Rasul, S. (2026). Intraprostatic PSMA PET/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(8), 4905-4912. https://doi.org/10.1007/s00259-026-07839-w
Vancouver
Einspieler H, Nürnberger M, Spielvogel CP, Nics L, Baltzer PAT, Huebner N, et al. Intraprostatic PSMA PET/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(8):4905-4912. doi:10.1007/s00259-026-07839-w
BibTeX
@article{Einspieler2026,
author = {Einspieler, Holger and Nürnberger, Michael and Spielvogel, Clemens P and Nics, Lukas and Baltzer, Pascal A T and Huebner, Nicolai and Kramer, Gero and Shariat, Shahrokh F and Grubmüller, Bernhard and Hacker, Marcus and Rasul, Sazan},
title = {Intraprostatic PSMA PET/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {8},
pages = {4905--4912},
doi = {10.1007/s00259-026-07839-w}
}
EUVIMED